Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Musculoskeletal | Family Medicine
Disease Category: Multiple Sclerosis
Location: United States, IL
Clinical Trial Details
Research Study Summary
A 6 month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5mg/day in patients with relapsing remitting MS who are candidates for MS therapy change from previous disease modifying therapy (EPOC).
The purpose of this study is to evaluate patient-reported outcomes and physician assessment of a change in therapy for patients with remitting-relapsing multiple sclerosis when changing a patient's current multiple sclerosis therapy to fingolimod or maintaining the current therapy.
Please contact Alexian Brothers for more information on participation.
To Learn more
Both Male and Female
Date Last Changed:
July 22, 2013
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.